Product Code: GVR-3-68038-114-6
Inflammatory Bowel Disease Treatment Market Growth & Trends:
The global inflammatory bowel disease treatment market size is expected to reach USD 27.0 billion, expanding at a CAGR of 3.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of the disease, the surge in awareness about inflammatory bowel disease among people, and favorable regulatory scenarios are projected to drive the inflammatory bowel disease treatment market over the forecast period. For instance, in December 2022, Pfizer Inc. announced the U.S. FDA acceptance for review of an NDA for etrasimod for patients having severe ulcerative colitis. The favorable initiatives undertaken by regulatory authorities for treatment designations and approval of novel drugs for the management of inflammatory bowel disease are fueling market expansion.
The increasing collaboration of market players and non-profit organizations to counter various challenges in the development of novel therapeutics for IBD treatment is projected to propel market growth. For instance, in October 2022, Verily, a precision health company and the Crohn's & Colitis Foundation expanded their strategic collaboration to accelerate research in ulcerative colitis and Crohn's disease. In addition, the European Crohn's and Colitis Organization has taken several favorable steps to improve the care of patients living with inflammatory bowel disease.
Recently approved novel drugs such as filgotinib, ozanimod, upadacitinib, and risankizumab for the treatment of inflammatory bowel disease are expected to support market growth in the coming years. Moreover, the regulatory authorities are encouraging manufacturers to develop novel therapeutic approaches for rare and life-threatening diseases. For instance, in December 2020, Thetis Pharmaceuticals received an orphan drug designation for TP-317 from the U.S. FDA for pediatric ulcerative colitis. Such favorable initiatives are expected to boost the R&D activities to develop novel therapeutic products for IBD.
Furthermore, the rising demand & approvals for biosimilars for the treatment of various inflammatory conditions is a high-impact rendering factor for the market. For instance, in December 2022, the U.S. FDA approved Idacio as an eighth adalimumab biosimilar in the U.S. The newly approved biosimilar is a citrate-free low-concentration preparation intended for the treatment of several inflammatory conditions, including CD in adults and children aged 6 years or older. In addition, in October 2021, the U.S. FDA approved Cyltezo for the management of moderate to severe CD and UC. Moreover, the increasing introduction of biosimilars is expected to boost the adoption of biological products for the treatment of IBD in developing economies.
Moreover, government bodies are taking efforts to promote the uptake of biosimilars with their safe use. For instance, in October 2022, the government of Saskatchewan launched a biosimilar initiative to help its residents to access high-quality therapeutics at a lesser cost. Similarly, provinces like Ontario and Quebec in Canada are also expanding biosimilar initiatives to promote the uptake of biosimilar candidates.
Inflammatory Bowel Disease Market Report Highlights:
- The Crohn's disease segment held the largest share owing to the increasing prevalence of the condition and the high prescription rate of biologics for the treatment of the disease
- The ulcerative colitis segment is poised to register the fastest growth rate due to the rising approval of biologics for the treatment of ulcerative colitis and the high patient base
- The TNF inhibitors segment accounted for the largest market share in 2022 owing to the high prescription rate for the treatment of IBD and rising consumer awareness about TNF inhibitors
- Based on the route of administration, the injectable segment dominated the inflammatory bowel disease treatment market in 2022, whereas the oral segment is anticipated to be the fastest-growing segment
- The hospital pharmacy segment was the largest in 2022, owing to higher hospitalization rates and favorable reimbursement coverage
- Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the rising investments by market players and increasing disease prevalence in the region
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Segment scope
- 1.1.2 Regional scope
- 1.1.3 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased database:
- 1.3.2 GVR's internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach: Commodity Flow Approach
- 1.7 Research Assumptions
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2
- 1.10.3 Objective 3
- 1.10.4 Objective 4
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Competitive Insights
Chapter 3 Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope
- 3.1 Market Lineage Outlook
- 3.2 Market Dynamics
- 3.2.1 Market drivers analysis
- 3.2.1.1 Robust product pipeline
- 3.2.1.2 High prevalence of crohn's disease and ulcerative colitis
- 3.2.1.3 Increasing geriatric population
- 3.2.2 Market restraint analysis
- 3.2.2.1 High number of patent expirations
- 3.2.2.2 High cost of treatment
- 3.3 Penetration & Growth Prospect Mapping
- 3.4 Gastrointestinal Therapeutics: Market Analysis Tools
- 3.4.1 Industry analysis- Porter's
- 3.4.2 PESTLE analysis
- 3.5 Regulatory Framework
- 3.6 Pricing Analysis
Chapter 4 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Type, 2018 - 2030 (USD Million)
- 4.1 Definition and Scope
- 4.2 Type Market Share Analysis, 2022 & 2030
- 4.3 Segment Dashboard
- 4.4 Global Inflammatory Bowel Disease Treatment Market, by Type, 2018 to 2030
- 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 4.5.1 Crohn's Disease
- 4.5.1.1 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.2 Ulcerative Colitis
- 4.5.2.1 Ulcerative colitis market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Drug Class 2018 - 2030 (USD Million)
- 5.1 Definition and Scope
- 5.2 Drug Class Market Share Analysis, 2022 & 2030
- 5.3 Segment Dashboard
- 5.4 Global Inflammatory Bowel Disease Treatment Market, by Drug Class, 2018 to 2030
- 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 5.5.1 Aminosalicylates
- 5.5.1.1 Aminosalicylates market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.2 Corticosteroids
- 5.5.2.1 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.3 TNF inhibitors
- 5.5.3.1 TNF inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.4 IL inhibitors
- 5.5.4.1 IL inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.5 Anti-integrin
- 5.5.5.1 Anti-integrin market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.6 JAK inhibitors
- 5.5.6.1 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
- 5.5.7 Others
- 5.5.7.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Route of Administration, 2018 - 2030 (USD Million)
- 6.1 Definition and Scope
- 6.2 Route of Administration Market Share Analysis, 2022 & 2030
- 6.3 Segment Dashboard
- 6.4 Global Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2018 to 2030
- 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 6.5.1 Oral
- 6.5.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.2 Injectable
- 6.5.2.1 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
- 7.1 Definition and Scope
- 7.2 Distribution Channel Market Share Analysis, 2022 & 2030
- 7.3 Segment Dashboard
- 7.4 Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2018 to 2030
- 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 7.5.1 Hospital Pharmacy
- 7.5.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.2 Retail Pharmacy
- 7.5.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.3 Online Pharmacy
- 7.5.3.1 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8 Inflammatory Bowel Disease Treatment Market Segment Analysis, By Region, 2018 - 2030 (USD Million)
- 8.1 Definition & Scope
- 8.2 Regional Market Share Analysis, 2022 & 2030
- 8.3 Regional Market Dashboard
- 8.4 Regional Market Snapshot
- 8.5 SWOT Analysis
- 8.5.1 North America
- 8.5.2 Europe
- 8.5.3 Asia Pacific
- 8.5.4 Latin America
- 8.5.5 Middle East and Africa
- 8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
- 8.6.1 North America
- 8.6.1.1 North America inflammatory bowel disease treatment market , 2018 - 2030 (USD Million)
- 8.6.1.2 U.S.
- 8.6.1.2.1 Key Country Dynamics
- 8.6.1.2.2 Competitive Scenario
- 8.6.1.2.3 Regulatory Framework
- 8.6.1.2.4 Reimbursement Scenario
- 8.6.1.2.5 U.S. inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.1.3 Canada
- 8.6.1.3.1 Key Country Dynamics
- 8.6.1.3.2 Competitive Scenario
- 8.6.1.3.3 Regulatory Framework
- 8.6.1.3.4 Reimbursement Scenario
- 8.6.1.3.5 Canada inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2 Europe
- 8.6.2.1 Europe inflammatory bowel disease treatment market, 2018 - 2030 (USD Million)
- 8.6.2.2 UK
- 8.6.2.2.1 Key Country Dynamics
- 8.6.2.2.2 Competitive Scenario
- 8.6.2.2.3 Regulatory Framework
- 8.6.2.2.4 Reimbursement Scenario
- 8.6.2.2.5 UK inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.3 Germany
- 8.6.2.3.1 Key Country Dynamics
- 8.6.2.3.2 Competitive Scenario
- 8.6.2.3.3 Regulatory Framework
- 8.6.2.23.4 Reimbursement Scenario
- 8.6.2.3.5 Germany inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.4 Spain
- 8.6.2.4.1 Key Country Dynamics
- 8.6.2.4.2 Competitive Scenario
- 8.6.2.4.3 Regulatory Framework
- 8.6.2.4.4 Reimbursement Scenario
- 8.6.2.4.5 Spain inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.5 France
- 8.6.2.5.1 Key Country Dynamics
- 8.6.2.5.2 Competitive Scenario
- 8.6.2.5.3 Regulatory Framework
- 8.6.2.5.4 Reimbursement Scenario
- 8.6.2.5.5 France inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.6 Italy
- 8.6.2.6.1 Key Country Dynamics
- 8.6.2.6.2 Competitive Scenario
- 8.6.2.6.3 Regulatory Framework
- 8.6.2.6.4 Reimbursement Scenario
- 8.6.2.6.5 Italy inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.7 Denmark
- 8.6.2.7.1 Key Country Dynamics
- 8.6.2.7.2 Competitive Scenario
- 8.6.2.7.3 Regulatory Framework
- 8.6.2.7.4 Reimbursement Scenario
- 8.6.2.7.5 Denmark inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.8 Sweden
- 8.6.2.8.1 Key Country Dynamics
- 8.6.2.8.2 Competitive Scenario
- 8.6.2.8.3 Regulatory Framework
- 8.6.2.8.4 Reimbursement Scenario
- 8.6.2.8.5 Sweden inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.2.9 Norway
- 8.6.2.9.1 Key Country Dynamics
- 8.6.2.9.2 Competitive Scenario
- 8.6.2.9.3 Regulatory Framework
- 8.6.2.9.4 Reimbursement Scenario
- 8.6.2.9.5 Norway inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3 Asia Pacific
- 8.6.3.1 Asia Pacific inflammatory bowel disease treatment market, 2018 - 2030 (USD Million)
- 8.6.3.2 Japan
- 8.6.3.2.1 Key Country Dynamics
- 8.6.3.2.2 Competitive Scenario
- 8.6.3.2.3 Regulatory Framework
- 8.6.3.2.4 Reimbursement Scenario
- 8.6.3.2.5 Japan inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.3 China
- 8.6.3.3.1 Key Country Dynamics
- 8.6.3.3.2 Competitive Scenario
- 8.6.3.3.3 Regulatory Framework
- 8.6.3.3.4 Reimbursement Scenario
- 8.6.3.3.5 China inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.4 India
- 8.6.3.4.1 Key Country Dynamics
- 8.6.3.4.2 Competitive Scenario
- 8.6.3.4.3 Regulatory Framework
- 8.6.3.4.4 Reimbursement Scenario
- 8.6.3.4.5 India inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.5 South Korea
- 8.6.3.5.1 Key Country Dynamics
- 8.6.3.5.2 Competitive Scenario
- 8.6.3.5.3 Regulatory Framework
- 8.6.3.5.4 Reimbursement Scenario
- 8.6.3.25.5 South Korea inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.6 Australia
- 8.6.3.6.1 Key Country Dynamics
- 8.6.3.6.2 Competitive Scenario
- 8.6.3.6.3 Regulatory Framework
- 8.6.3.6.4 Reimbursement Scenario
- 8.6.3.6.5 Australia inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.7 Thailand
- 8.6.3.7.1 Key Country Dynamics
- 8.6.3.7.2 Competitive Scenario
- 8.6.3.7.3 Regulatory Framework
- 8.6.3.7.4 Reimbursement Scenario
- 8.6.3.7.5 Thailand inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.3.8 Singapore
- 8.6.3.8.1 Key Country Dynamics
- 8.6.3.8.2 Competitive Scenario
- 8.6.3.8.3 Regulatory Framework
- 8.6.3.8.4 Reimbursement Scenario
- 8.6.3.8.5 Thailand inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.4 Latin America
- 8.6.4.1 Latin America inflammatory bowel disease treatment market, 2018 - 2030 (USD Million)
- 8.6.4.2 Brazil
- 8.6.4.2.1 Key Country Dynamics
- 8.6.4.2.2 Competitive Scenario
- 8.6.4.2.3 Regulatory Framework
- 8.6.4.2.4 Reimbursement Scenario
- 8.6.4.2.5 Brazil inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.4.3 Mexico
- 8.6.4.3.1 Key Country Dynamics
- 8.6.4.3.2 Competitive Scenario
- 8.6.4.3.3 Regulatory Framework
- 8.6.4.3.4 Reimbursement Scenario
- 8.6.4.3.5 Mexico inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.4.4 Argentina
- 8.6.4.4.1 Key Country Dynamics
- 8.6.4.4.2 Competitive Scenario
- 8.6.4.4.3 Regulatory Framework
- 8.6.4.4.4 Reimbursement Scenario
- 8.6.4.4.5 Argentina inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.5 MEA
- 8.6.5.1 MEA inflammatory bowel disease treatment market, 2018 - 2030 (USD Million)
- 8.6.5.2 South Africa
- 8.6.5.2.1 Key Country Dynamics
- 8.6.5.2.2 Competitive Scenario
- 8.6.5.2.3 Regulatory Framework
- 8.6.5.2.4 Reimbursement Scenario
- 8.6.5.2.5 South Africa inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.5.3 Saudi Arabia
- 8.6.5.3.1 Key Country Dynamics
- 8.6.5.3.2 Competitive Scenario
- 8.6.5.3.3 Regulatory Framework
- 8.6.5.3.4 Reimbursement Scenario
- 8.6.5.3.5 Saudi Arabia inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.5.4 UAE
- 8.6.5.4.1 Key Country Dynamics
- 8.6.5.4.2 Competitive Scenario
- 8.6.5.4.3 Regulatory Framework
- 8.6.5.4.4 Reimbursement Scenario
- 8.6.5.4.5 UAE inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
- 8.6.5.5 Kuwait
- 8.6.5.5.1 Key Country Dynamics
- 8.6.5.5.2 Competitive Scenario
- 8.6.5.5.3 Regulatory Framework
- 8.6.5.5.4 Reimbursement Scenario
- 8.6.5.5.5 Kuwait inflammatory bowel disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9 Inflammatory Bowel Disease Treatment Market- Competitive Analysis
- 9.1 Recent Developments & Impact Analysis, by Key Market Participants
- 9.1.1 Ansoff matrix
- 9.1.2 Heat map analysis
- 9.1.3 Major Deals and Strategic Alliances Analysis
- 9.1.3.1 Joint Ventures
- 9.1.3.2 Licensing Agreements
- 9.1.3.3 Product Launches
- 9.1.3.4 Conferences and Campaigns
- 9.2 Company Categorization
- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.3 Vendor Landscape
- 9.3.1 List of key distributors and channel partners
- 9.3.2 Key customers
- 9.4 Public Companies
- 9.4.1 Competitive Dashboard Analysis
- 9.4.1.1 Market Differentiators
- 9.5 Private Companies
- 9.5.1 List of key emerging companies
- 9.6 Company Profiles
- 9.6.1 AbbVie Inc
- 9.6.1.1 Company overview
- 9.6.1.2 Financial performance
- 9.6.1.3 Product benchmarking
- 9.6.1.4 Strategic Initiatives
- 9.6.2 Biogen
- 9.6.2.1 Company overview
- 9.6.2.2 Financial performance
- 9.6.2.3 Product benchmarking
- 9.6.2.4 Strategic Initiatives
- 9.6.3 Takeda Pharmaceutical Company Limited
- 9.6.3.1 Company overview
- 9.6.3.2 Financial performance
- 9.6.3.3 Product benchmarking
- 9.6.3.4 Strategic Initiatives
- 9.6.4 Novartis AG
- 9.6.4.1 Company overview
- 9.6.4.2 Financial performance
- 9.6.4.3 Product benchmarking
- 9.6.4.4 Strategic Initiatives
- 9.6.5 Pfizer Inc
- 9.6.5.1 Company overview
- 9.6.5.2 Financial performance
- 9.6.5.3 Product benchmarking
- 9.6.5.4 Strategic Initiatives
- 9.6.6 Lilly
- 9.6.6.1 Company overview
- 9.6.6.2 Financial performance
- 9.6.6.3 Product benchmarking
- 9.6.6.4 Strategic Initiatives
- 9.6.7 UCB S.A.
- 9.6.7.1 Company overview
- 9.6.7.2 Financial performance
- 9.6.7.3 Product benchmarking
- 9.6.7.4 Strategic initiatives
- 9.6.8 Johnson & Johnson Services, Inc.
- 9.6.8.1 Company overview
- 9.6.8.2 Financial performance
- 9.6.8.3 Product benchmarking
- 9.6.8.4 Strategic initiatives
- 9.6.9 CELLTRION INC
- 9.6.9.1 Company overview
- 9.6.9.2 Financial performance
- 9.6.9.3 Product benchmarking
- 9.6.9.4 Strategic initiatives
- 9.6.10 Merck & Co., Inc
- 9.6.10.1 Company overview
- 9.6.10.2 Financial performance
- 9.6.10.3 Product benchmarking
- 9.6.10.4 Strategic initiatives